Sumitomo Dainippon Pharma, headquartered in Japan, along with Sunovion Pharma, its subsidiary in Massachusetts, are seeking digital biomarkers that can be applied to mental disorders. The company would like to hear about all innovative technology related to this area and, in particular, digital measures that correlate with a number of patient symptoms (see examples below). Detection and/or data collection via smartphones or wearable devices would be a plus. The main application is monitoring as part of clinical trials
Example Symptoms of Interest
The meeting will be with company representatives involved with clinical trial monitoring.
* Note this is a meeting opportunity, meaning there may or may not be a defined project as of the meeting. The purpose of the meeting is mutual discovery: for you to learn about the company's problem and for them to learn about your products and services. If there's mutual match, that could lead to more.
In your response, please
Disclaimer: MIT Startup Exchange can make introductions that ideally provide open ended discussions in order to share mutual interests and potentially create common ground that incite the parties to collaborate. MIT Startup Exchange introductions may eventually lead to mutual partnerships, but that is not in any way guaranteed by MIT, MIT Corporate Relations, MIT Industrial Liaison Program (ILP) or MIT Startup Exchange, which takes no responsibility for these outcomes and no formal part in such discussions following our introduction. MIT Startup Exchange and its activities and events are not for purposes of soliciting investment or offering securities.